Establishment and characterization of NCC-SFT1-C1: a novel patient-derived cell line of solitary fibrous tumor.

Solitary fibrous tumors (SFTs) are rare mesenchymal tumors characterized by recurrent NAB2::STAT6 gene fusion, which are associated with an unpredictable clinical course, including the potential for recurrence or metastasis. Current therapeutic approaches for relapsed cases remain ineffective, and there is no established standard of care for SFTs. Although patient-derived cancer cell lines are fundamental research tools, only a few cell lines have been developed for SFTs. To address this, we established a novel SFT cell line, NCC-SFT1-C1, derived from surgically resected tumor tissues of a patient with SFT. The cell line retains the characteristic recurrent NAB2::STAT6 gene fusion in concordance with the matched original tumor. These cells exhibit moderate proliferation, invasion ability, and spheroid formation. We demonstrated that NCC-SFT1-C1 cells are useful for the high-throughput screening of the antiproliferative effects of 221 oncology drugs. Therefore, the NCC-SFT1-C1 cell line is a valuable tool for basic and preclinical studies on SFT.